retatrutide phase 2 trial new england journal of medicine Number 1 Top Cardiometabolic Story 2023: with #retatrutide, a GIP-GLP-1-GCG receptor triple agonist, resulted in a mean weight reduction of 24.2% after 48 weeks. https://t.co/aED6xEFDI3 In the REDEFINE 1 phase
Description
its the price of a vial
A direct relationship exists between the extent of weight loss and the improvement observed in MAFLD
Check out our top stories of the year
In clinical trials, Tesamorelin did not significantly worsen overall glucose tolerance
